Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 10;13:987816. doi: 10.3389/fphar.2022.987816

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Remuzzi, Schiaffino, Santoro, FitzGerald, Melino and Patrono.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Summary of treatment spectrum for COVID-19. The panel shows drugs/biologics recommended or not recommended for treating patients with COVID-19. There are also medicines for which there is insufficient evidence to recommend for or against their use in these patients, as well as drugs/biologics and cell-based therapies that are under investigation. Concomitant medications used to treat underlying conditions in COVID-19 patients should also be taken into consideration for safety reasons. Managing treatment for children with Multisystem inflammatory syndrome, an illness that is temporally associated with preceding SARS-CoV-2 exposure is also mentioned.